

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: December 20, 2004, 15:06:06 ; Search time 75 Seconds  
(without alignments)  
416.126 Million cell updates/sec

Title: US-10-670-911a-1  
Perfect score: 480  
Sequence: 1 AGKCDVAFGFSQDLKLG.....RKESKLNIGSLFELCSG 87

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 2002273 seqs, 358729229 residues  
Total number of hits satisfying chosen parameters: 2002273

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : A\_Geneseq\_23Sep04:\*  
1: geneseqp1980s:\*  
2: geneseqp1990s:\*  
3: geneseqp2000s:\*  
4: geneseqp2001s:\*  
5: geneseqp2002s:\*  
6: geneseqp2003as:\*  
7: geneseqp2003bs:\*  
8: geneseqp2004s:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	480	100.0	87	ADM82927	Soluble c
2	480	100.0	142	AAW37859	Human neu
3	480	100.0	142	AAW37858	Rat neur
4	480	100.0	142	AAI10235	Human fet
5	480	100.0	142	AAW39848	Human pol
6	480	100.0	142	ADBE63108	Rat Prote
7	480	100.0	142	ADBE63114	Human Pro
8	480	100.0	142	ADBE63112	Rat Prote
9	480	100.0	142	ADBE63110	Human Pro
10	480	100.0	142	ADN04842	Antipso
11	480	100.0	154	AAW41634	Human pol
12	426.5	88.9	143	AAW89078	Polypepti
13	426.5	88.9	143	ABW51249	Human sec
14	426.5	88.9	143	ABO45506	Novel hum
15	426.5	88.9	143	ABO26886	Protein a
16	359.5	74.9	157	ABO26886	Novel hum
17	339	70.6	116	AAW59990	Human end
18	327	68.1	90	AAW89077	Polypepti
19	327	68.1	90	ABW51248	Human sec
20	327	68.1	90	ABO45505	Novel hum
21	327	68.1	90	ABO26885	Protein a
22	179.5	37.4	127	AAW44088	Human sec
23	179.5	37.4	127	AAW27652	Secreted
24	179.5	37.4	164	AAW01380	Neuron-as
25	179.5	37.4	165	AAW50972	Human PRO

26	179.5	37.4	165	AAW39830	Human pol
27	179.5	37.4	165	AAW83706	Human PRO
28	179.5	37.4	165	AAW86146	Human PRO
29	179.5	37.4	165	ABW84968	Human PRO
30	179.5	37.4	165	ABW85574	Human ang
31	179.5	37.4	165	ABW80853	Human PRO
32	179.5	37.4	165	ABO33819	Novel hum
33	179.5	37.4	165	ABU71438	Human nec
34	179.5	37.4	165	ABU82162	Novel hum
35	179.5	37.4	165	ABU72342	Human PRO
36	179.5	37.4	165	ABU72470	Human PRO
37	179.5	37.4	165	ABU72470	Human PRO
38	179.5	37.4	165	ABU72172	Human mem
39	179.5	37.4	165	ABW83720	Novel hum
40	179.5	37.4	165	ABW80826	Novel hum
41	179.5	37.4	165	ADB73367	Novel hum
42	179.5	37.4	165	ADB78449	Novel hum
43	179.5	37.4	165	ADW85097	Human PRO
44	179.5	37.4	165	ADW78203	Novel hum
45	179.5	37.4	165	ADW87269	Human PRO

## ALIGNMENTS

RESULT 1  
ADM82927 standard; protein; 87 AA.  
XX  
AC ADM82927;  
XX  
DT 01-JUL-2004 (first entry)  
XX  
DE Soluble candidate plasticity gene s-CPG15 core domain SEQ ID NO:1.  
XX  
KW cell death; soluble candidate plasticity gene; s-CPG15; CNS; cardiac;  
KW gene therapy; Alzheimer's disease; Parkinson's disease;  
KW Huntington's disease; amyotrophic lateral sclerosis;  
KW traumatic brain injury; stroke; cardiac condition; cardiac ischemia;  
KW s-CPG15 core domain.  
XX  
OS Homo sapiens.  
XX  
PN WO2004031347-A2.  
XX  
PD 15-APR-2004.  
XX  
PF 24-SEP-2003; 2003WO-US030152.  
XX  
PR 24-SEP-2002; 2002US-0413238P.  
XX  
PA (MAST) MASSACHUSETTS INST TECHNOLOGY.  
XX  
PI Medivl E, Putz U;  
XX  
DR WPI; 2004-330162/30.  
XX  
PT Treating or preventing a condition of excessive cell death in a subject  
PT comprising administering to the subject a soluble CPG15 (s-CPG15) compound  
PT having s-CPG15 biological activity.  
XX  
PS Claim 5; SEQ ID NO 1; 92pp; English.  
XX  
The present invention describes a method for treating or preventing a  
condition of excessive cell death in a subject, which comprises  
administering to the subject a soluble candidate plasticity gene CPG15 (s-CPG15) compound having s-CPG15 biological activity in an amount and for  
a time sufficient to prevent, reduce, or eliminate the symptoms of the  
condition. Also described: (1) a method of reducing or preventing cell  
death by administering to a cell s-CPG15 in an amount and for a time to  
reduce or prevent the cell death; (2) a method of promoting the survival  
or differentiation of a cell by administering to the cell s-CPG15; (3) a  
composition of matter comprising a purified polypeptide having s-CPG15

biological activity; (4) methods of treating or preventing a condition of undruggable cell survival in a subject; (5) methods of enhancing cell death; (6) a composition of matter comprising a purified antibody or antigen-binding fragment that specifically binds s-CPG15; (7) a method of manufacturing s-CPG15 by expressing the s-CPG15 protein in a population of cells and isolating from the supernatant of the cell population the s-CPG15; and (8) a method of identifying a candidate compound that modulates cell death, cell survival, or cellular differentiation pathways. s-CPG15 has CNS and cardiac activities, and can be used in gene therapy. The methods are useful for treating or preventing Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic injury to the brain, or stroke, or a cardiac condition such as cardiac ischemia. The present sequence represents a specifically claimed s-CPG15 core domain amino acid sequence from the present invention.

Sequence 87 AA:

Query Match 100.0%; Score 480; DB 8; Length 87;  
Best Local Similarity 100.0%; Pred. No. 7e-51;  
Matches 87; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 AGKCDVAFKGFSDCLLKLGDPMANYPQGLDDKTNIKTVCTYWEDEFHSCVTALTDCQEGA 60  
1 AGKCDVAFKGFSDCLLKLGDPMANYPQGLDDKTNIKTVCTYWEDEFHSCVTALTDCQEGA 60  
61 KDMWDKLRKESKXNLNIGSLFELCGSG 87  
61 KDMWDKLRKESKXNLNIGSLFELCGSG 87

#### RESULT 2

AAW37859 standard; protein; 142 AA.

AAW37859;

10-AUG-1998 (first entry)

Human neuritin full length amino acid sequence.

Human neuritin; antibody; autonomic nervous system; Parkinson's disease; CNS; peripheral nervous system; Alzheimer's disease; tissue implantation.

Homo sapiens.

MO9806843-A1.

19-FEB-1998.

07-AUG-1997; 97MO-US013949.

09-AUG-1996; 96US-00694579.

(AMGE-) AMGEN INC.  
(YEDA) YEDA RES & DEV CO LTD.

Theill LE, Naeve GS;

WPI; 1998-159535/14.

N-PSDB; AAV29022.

New isolated neuritin gene - is used to develop products for treating e.g. Alzheimer's disease, Parkinson's disease, peripheral neuropathy and damaged or degenerated nervous system tissue.

Claim 1; Fig 4; 83pp; English.

This is the full length amino acid sequence of the human neuritin. The gene products (e.g. antibody, peptide fragments, etc) can be used to treat patients in whom various cells of the central, autonomic, or peripheral nervous system have been degenerated, as well as treatment of

e.g. Alzheimer's disease, Parkinson's disease. They can also be used in conjunction with surgical implantation of tissue in the treatment of diseases in which tissue implantation is indicated. The products can also be used for detection and diagnosis

Sequence 142 AA:

Query Match 100.0%; Score 480; DB 2; Length 142;  
Best Local Similarity 100.0%; Pred. No. 1.3e-50;  
Matches 87; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 AGKCDVAFKGFSDCLLKLGDPMANYPQGLDDKTNIKTVCTYWEDEFHSCVTALTDCQEGA 60  
28 AGKCDVAFKGFSDCLLKLGDPMANYPQGLDDKTNIKTVCTYWEDEFHSCVTALTDCQEGA 87  
61 KDMWDKLRKESKXNLNIGSLFELCGSG 87  
88 KDMWDKLRKESKXNLNIGSLFELCGSG 114

#### RESULT 3

AAW37858 standard; protein; 142 AA.

AAW37858;

10-AUG-1998 (first entry)

Rat neuritin full length amino acid sequence.

Rat neuritin; antibody; autonomic nervous system; Parkinson's disease; CNS; peripheral nervous system; Alzheimer's disease; tissue implantation.

Rattus sp.

MO9806843-A1.

19-FEB-1998.

07-AUG-1997; 97MO-US013949.

09-AUG-1996; 96US-00694579.

(AMGE-) AMGEN INC.  
(YEDA) YEDA RES & DEV CO LTD.

Theill LE, Naeve GS;

WPI; 1998-159535/14.

N-PSDB; AAV29022.

New isolated neuritin gene - is used to develop products for treating e.g. Alzheimer's disease, Parkinson's disease, peripheral neuropathy and damaged or degenerated nervous system tissue.

Claim 1; Fig 3; 83pp; English.

This is the full length amino acid sequence of the rat neuritin. The gene products (e.g. antibody, peptide fragments etc) can be used to treat patients in whom various cells of the central, autonomic, or peripheral nervous system have been degenerated, as well as treatment of e.g. Alzheimer's disease, Parkinson's disease. They can also be used in conjunction with surgical implantation of tissue in the treatment of diseases in which tissue implantation is indicated. The products can also be used for detection and diagnosis

Sequence 142 AA:

Query Match 100.0%; Score 480; DB 2; Length 142;  
Best Local Similarity 100.0%; Pred. No. 1.3e-50;  
Matches 87; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 AGKCDVAFKGFSDCLLKLGDPMANYPQGLDDKTNIKTVCTYWEDEFHSCVTALTDCQEGA 60

DB 28 AAKCDAVFQGFSDCLLKLGDSWANYPGQLDCKTNIKTCTYWEFHSCVTALTDCQEGA 87  
QY 61 KQMDKLRKESKNLNIQGSLEFELCGSG 87  
DB 88 KQMDKLRKESKNLNIQGSLEFELCGSG 114

RESULT 4  
AAB10235  
ID AAB10235 standard; protein; 142 AA.  
XX  
AC AAB10235;  
XX  
DT 16-NOV-2000 (first entry)  
XX  
DE Human fetal brain protein fragment AS34\_11.  
XX  
KW Secreted protein; cytosolic; immunostimulatory; antimicrobial;  
KW antiviral; immunosuppressive; antiinflammatory; vulnerary; cytokine;  
KW cell proliferation; differentiation; regulator; treatment; tumor;  
KW autoimmune disease; inflammatory disorder; wound; microbial infection;  
KW viral disease; graft versus host reaction suppression.  
XX  
OS Homo sapiens.  
XX  
PN WO200037630-A1.  
XX  
PD 29-JUN-2000.  
XX  
PF 22-DEC-1999; 99WO-US031005.  
XX  
PR 23-DEC-1998; 98US-00220876.  
XX  
PA (GEMV) GENETICS INST INC.

XX  
PI Jacobs K, McCoy JM, Lavallie ER, Collins-Racie LA, Evans C;  
PI Weirberg D, Treacy M, Bowman MR;  
XX  
DR WPI: 2000-44261/38.  
DR N-PSDB; AAA40501.  
XX  
PT Secreted human proteins AS296-11 and AS34-11, useful for treating tumors,  
PT autoimmune diseases, inflammatory disorders, wounds, microbial infections  
PT and viral diseases.  
XX  
PS Claim 9a; Page 209-210; 293pp; English.  
XX  
XX

CC This invention describes novel treating human proteins (I) which have  
CC cytosolic, immunostimulatory, antimicrobial, antiviral,  
CC immunosuppressive, antiinflammatory and vulnerary activity and which act  
CC as cytokine, cell proliferation or differentiation regulators. (I) is  
CC useful for treating tumors, autoimmune diseases, inflammatory disorders,  
CC wounds, microbial infections and viral diseases. (I) is also useful for  
CC suppressing graft versus host reaction. AAB10226-B10288 represent the  
CC secreted proteins encoded by AAA40490-AAA0580 which are described in the  
CC method of the invention  
XX  
XX

SO Sequence 142 AA;  
Query Match 100.0%; Score 480; DB 3; Length 142;  
Best Local Similarity 100.0%; Pred. No. 1.3e-50;  
Matches 87; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AAGCDAVFQGFSDCLLKLGDSWANYPGQLDCKTNIKTCTYWEFHSCVTALTDCQEGA 60  
DB 28 AAKCDAVFQGFSDCLLKLGDSWANYPGQLDCKTNIKTCTYWEFHSCVTALTDCQEGA 87  
QY 61 KQMDKLRKESKNLNIQGSLEFELCGSG 87  
DB 88 KQMDKLRKESKNLNIQGSLEFELCGSG 114

RESULT 5  
AAM39848  
ID AAM39848 standard; protein; 142 AA.  
XX  
AC AAM39848;  
XX  
DT 22-OCT-2001 (first entry)  
XX  
DE Human polypeptide SEQ ID NO 2993.  
XX  
XX  
KW Human; nocotropic; immunosuppressant; cytosolic; gene therapy; cancer;  
KW peripheral nervous system; neuropathy; central nervous system; CNS;  
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;  
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;  
KW chemokine; thrombolytic; drug screening; arthritis; inflammation;  
KW leukaemia.  
XX  
OS Homo sapiens.  
XX  
PN WO200153312-A1.  
XX  
PD 26-JUL-2001.  
XX  
PF 26-DEC-2000; 2000WO-US034263.  
XX  
PR 23-DEC-1999; 99US-00471275.  
PR 21-JAN-2000; 2000US-00488725.  
PR 25-APR-2000; 2000US-00552317.  
PR 20-JUN-2000; 2000US-00598042.  
PR 19-JUL-2000; 2000US-00620312.  
PR 03-AUG-2000; 2000US-00653450.  
PR 14-SEP-2000; 2000US-00662191.  
PR 19-OCT-2000; 2000US-00693036.  
PR 29-NOV-2000; 2000US-00727344.  
XX  
PA (HISE-) HISE INC.

XX  
PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;  
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J, Zhao Qa;  
PI Zhou P, Goodrich R, Drmanac RT;  
XX  
DR WPI: 2001-442853/47.  
DR N-PSDB; AAI59004.  
XX  
PT Novel nucleic acids and polypeptides, useful for treating disorders such  
PT as central nervous system injuries.  
XX  
PS Example 4; SEQ ID NO 2993; 10078pp; English.  
XX  
XX

CC The invention relates to human nucleic acids (AA157798-AA161369) and the  
CC encoded polypeptides (AAM8642-AAM42213) with nocotropic,  
CC immunosuppressant and cytosolic activity. The polynucleotides are useful  
CC in gene therapy. A composition containing a polypeptide or polynucleotide  
CC system, such as peripheral nervous injuries, peripheral neuropathy and  
CC localized neuropathies and central nervous system diseases, such as  
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic  
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the  
CC utilisation of the activities such as: Immune system suppression,  
CC Activin/Inhibin activity, chemotactic/chemokinetic activity, haemostatic  
CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,  
CC assays for receptor activity, arthritis and inflammation, leukaemias and  
CC C.N.S disorders. Note: The sequence data for this patent did not form  
CC part of the printed specification  
XX  
XX

SO Sequence 142 AA;  
Query Match 100.0%; Score 480; DB 4; Length 142;  
Best Local Similarity 100.0%; Pred. No. 1.3e-50;  
Matches 87; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AAGCDAVFQGFSDCLLKLGDSWANYPGQLDCKTNIKTCTYWEFHSCVTALTDCQEGA 60

Db 28 AGKCDAVFKGSPDCLLKLGDPMANYPQGLDKNIKVCTYWMDFHSCVTALTDCQEGA 87  
QY 61 KDMWDKLRKESKRNLTNGSLFELCGSG 87  
Db 88 KDMWDKLRKESKRNLTNGSLFELCGSG 114

RESULT 6  
ADE63108  
ADE63108 standard; protein; 142 AA.

AC ADE63108;  
XX  
XX  
XX 29-JAN-2004 (first entry)  
XX  
XX  
XX Rat Protein AAB53415, SEQ ID NO 9043.  
XX  
XX Rat; pain; neuronal tissue; gene therapy; spinal segmental nerve injury;  
XX  
XX chronic constriction injury; CCI; spared nerve injury; SNI; Chung.  
XX  
XX Rattus norvegicus.  
XX  
XX W02003016475-A2.  
XX  
XX 27-FEB-2003.  
XX  
XX 14-AUG-2002; 2002WO-05025765.  
XX  
XX 14-AUG-2001; 2001US-0312147P.  
XX  
XX 01-NOV-2001; 2001US-0346382P.  
XX  
XX 26-NOV-2001; 2001US-0333347P.  
XX  
XX (GENO ) GEN HOSPITAL CORP.  
XX  
XX (FARB ) BAYER AG.  
XX  
XX Woolf C, D'urso D, Befort K, Costigan M;  
XX  
XX WPI; 2003-268312/26.  
XX  
XX GENBANK; AAB53415.  
XX  
XX  
XX New composition comprising two or more isolated polypeptides, useful for  
XX  
XX preparing a medicament for treating pain in an animal.  
XX  
XX  
XX Claim 1; Page; 1017pp; English.

CC The invention discloses a composition comprising two or more isolated rat  
CC or human polynucleotides or a polynucleotide which represents a fragment,  
CC derivative or allelic variation of the nucleic acid sequence. Also  
CC claimed are a vector comprising the novel polynucleotide, a host cell  
CC comprising the vector, a method for identifying a nucleotide sequence  
CC which is differentially regulated in an animal subjected to pain and a  
CC kit to perform the method, an array, a method for identifying an agent  
CC that increases or decreases the expression of the polynucleotide sequence  
CC that is differentially expressed in neuronal tissue of a first animal  
CC subjected to pain, a method for identifying a compound which regulates  
CC the expression of a polynucleotide sequence which is differentially  
CC expressed in an animal subjected to pain, a method for identifying a  
CC compound that regulates the activity of one or more of the  
CC polynucleotides, a method for producing a pharmaceutical composition, a  
CC method for identifying a compound or small molecule that regulates the  
CC activity in an animal of one or more of the polypeptides given in the  
CC specification, a method for identifying a compound useful in treating  
CC pain and a pharmaceutical composition comprising the one or more  
CC polypeptides or their antibodies. The polynucleotide or the compound that  
CC modulates its activity is useful for preparing a medicament for treating  
CC pain (e.g. spinal segmental nerve injury (Chung), chronic constriction  
CC injury (CCI) and spared nerve injury (SNI)) in an animal (e.g. gene  
CC therapy). The sequence presented is a rat protein (shown in Table 2 of  
CC the specification) which is differentially expressed during pain. Note:  
CC the sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic form directly from WIPO at  
CC [http://wipo.int/pub/published\\_pct\\_sequences](http://wipo.int/pub/published_pct_sequences).

SEQ Sequence 142 AA;  
Query Match 100.0%; Score 480; DB 7; Length 142;  
Best Local Similarity 100.0%; Pred. No. 1,3e-50;  
Matches 87; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGKCDAVFKGSPDCLLKLGDPMANYPQGLDKNIKVCTYWMDFHSCVTALTDCQEGA 60  
Db 28 AGKCDAVFKGSPDCLLKLGDPMANYPQGLDKNIKVCTYWMDFHSCVTALTDCQEGA 87  
QY 61 KDMWDKLRKESKRNLTNGSLFELCGSG 87  
Db 88 KDMWDKLRKESKRNLTNGSLFELCGSG 114

RESULT 7  
ADE63114  
ADE63114 standard; protein; 142 AA.

AC ADE63114;  
XX  
XX  
XX 29-JAN-2004 (first entry)  
XX  
XX  
XX Human Protein NP\_057672, SEQ ID NO 9049.  
XX  
XX  
XX Human; pain; neuronal tissue; gene therapy;  
XX  
XX spinal segmental nerve injury; chronic constriction injury; CCI;  
XX  
XX spared nerve injury; SNI; Chung.  
XX  
XX Homo sapiens.  
XX  
XX W02003016475-A2.  
XX  
XX 27-FEB-2003.  
XX  
XX 14-AUG-2002; 2002WO-05025765.  
XX  
XX 14-AUG-2001; 2001US-0312147P.  
XX  
XX 01-NOV-2001; 2001US-0346382P.  
XX  
XX 26-NOV-2001; 2001US-0333347P.  
XX  
XX (GENO ) GEN HOSPITAL CORP.  
XX  
XX (FARB ) BAYER AG.  
XX  
XX Woolf C, D'urso D, Befort K, Costigan M;  
XX  
XX WPI; 2003-268312/26.  
XX  
XX GENBANK; NP\_057672.  
XX  
XX  
XX New composition comprising two or more isolated polypeptides, useful for  
XX  
XX preparing a medicament for treating pain in an animal.  
XX  
XX  
XX Claim 1; Page; 1017pp; English.

CC The invention discloses a composition comprising two or more isolated rat  
CC or human polynucleotides or a polynucleotide which represents a fragment,  
CC derivative or allelic variation of the nucleic acid sequence. Also  
CC claimed are a vector comprising the novel polynucleotide, a host cell  
CC comprising the vector, a method for identifying a nucleotide sequence  
CC which is differentially regulated in an animal subjected to pain and a  
CC kit to perform the method, an array, a method for identifying an agent  
CC that increases or decreases the expression of the polynucleotide sequence  
CC that is differentially expressed in neuronal tissue of a first animal  
CC subjected to pain, a method for identifying a compound which regulates  
CC the expression of a polynucleotide sequence which is differentially  
CC expressed in an animal subjected to pain, a method for identifying a  
CC compound that regulates the activity of one or more of the  
CC polynucleotides, a method for producing a pharmaceutical composition, a  
CC method for identifying a compound or small molecule that regulates the  
CC activity in an animal of one or more of the polypeptides given in the  
CC specification, a method for identifying a compound useful in treating  
CC pain and a pharmaceutical composition comprising the one or more  
CC polypeptides or their antibodies. The polynucleotide or the compound that

modulates its activity is useful for preparing a medicament for treating pain (e.g. spinal segmental nerve injury (Chung), chronic constriction injury (CCI) and spared nerve injury (SNI)) in an animal (e.g. gene therapy). The sequence presented is a human protein (shown in Table 2 of the specification) which is differentially expressed during pain. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic form directly from WIPO at ftp.wipo.int/pub/published\_pct\_sequences.

Sequence 142 AA:

Query Match 100.0%; Score 480; DB 7; Length 142;  
Best Local Similarity 100.0%; Pred. No. 1.3e-50;  
Matches 87; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGKCDVAFKGFSDCLLKIGDSMANYPOGLDDKTNIKTYCTWEDFHSCTVTALDCEGA 60  
DB 28 AGKCDVAFKGFSDCLLKIGDSMANYPOGLDDKTNIKTYCTWEDFHSCTVTALDCEGA 87  
61 KDMWDKLRKESKNLNIQSLFELCGSG 87  
DB 88 KDMWDKLRKESKNLNIQSLFELCGSG 114

RESULT 8

ID ADE63112 standard; protein; 142 AA.

AC ADE63112;

DT 29-JAN-2004 (first entry)

DE Rat Protein AABS3415, SEQ ID NO 9047.

KW Rat; pain; neuronal tissue; gene therapy; spinal segmental nerve injury;

KM chronic constriction injury; CCI; spared nerve injury; SNI; Chung.

OS Rattus norvegicus;

PN W02003016475-A2.

PD 27-FEB-2003.

PF 14-AUG-2002; 2002WO-US025765.

XX 14-AUG-2001; 2001US-0312147P.

PR 01-NOV-2001; 2001US-0346382P.

PR 26-NOV-2001; 2001US-0333347P.

PA (GEHO) GEN HOSPITAL CORP.

PA (FARB) BAYER AG.

PI Woolf C, D'urso D, Befort K, Costigan M;

DR WPI; 2003-268312/26.

DR GENBANK; AABS3415.

PT New composition comprising two or more isolated polypeptides, useful for

PT preparing a medicament for treating pain in an animal.

XX Claim 1; Page; 1017p; English.

CC The invention discloses a composition comprising two or more isolated rat  
CC or human polynucleotides or a polynucleotide which represents a fragment,  
CC derivative or allelic variation of the nucleic acid sequence. Also  
CC claimed are a vector comprising the novel polynucleotide, a host cell  
CC comprising the vector, a method for identifying a nucleotide sequence  
CC which is differentially regulated in an animal subjected to pain and a  
CC kit to perform the method, an array, a method for identifying an agent  
CC that increases or decreases the expression of the polynucleotide sequence  
CC that is differentially expressed in neuronal tissue of a first animal  
CC subjected to pain, a method for identifying a compound which regulates  
CC the expression of a polynucleotide sequence which is differentially

expressed in an animal subjected to pain, a method for identifying a compound that regulates the activity of one or more of the polynucleotides, a method for producing a pharmaceutical composition, a method for identifying a compound or small molecule that regulates the activity in an animal of one or more of the polypeptides given in the specification, a method for identifying a compound useful in treating pain and a pharmaceutical composition comprising the one or more polypeptides or their antibodies. The polynucleotide or the compound that modulates its activity is useful for preparing a medicament for treating pain (e.g. spinal segmental nerve injury (SNI)) in an animal (e.g. gene therapy). The sequence presented is a rat protein (shown in Table 2 of the specification) which is differentially expressed during pain. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic form directly from WIPO at ftp.wipo.int/pub/published\_pct\_sequences.

Sequence 142 AA:

Query Match 100.0%; Score 480; DB 7; Length 142;  
Best Local Similarity 100.0%; Pred. No. 1.3e-50;  
Matches 87; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGKCDVAFKGFSDCLLKIGDSMANYPOGLDDKTNIKTYCTWEDFHSCTVTALDCEGA 60  
DB 28 AGKCDVAFKGFSDCLLKIGDSMANYPOGLDDKTNIKTYCTWEDFHSCTVTALDCEGA 87  
61 KDMWDKLRKESKNLNIQSLFELCGSG 87  
DB 88 KDMWDKLRKESKNLNIQSLFELCGSG 114

RESULT 9

ID ADE63110 standard; protein; 142 AA.

AC ADE63110;

DT 29-JAN-2004 (first entry)

DE Human Protein NP\_057672, SEQ ID NO 9045.

KW Human; pain; neuronal tissue; gene therapy;

KM spinal segmental nerve injury; chronic constriction injury; CCI;

KW spared nerve injury; SNI; Chung.

OS Homo sapiens.

PN W02003016475-A2.

PD 27-FEB-2003.

PF 14-AUG-2002; 2002WO-US025765.

XX 14-AUG-2001; 2001US-0312147P.

PR 01-NOV-2001; 2001US-0346382P.

PR 26-NOV-2001; 2001US-0333347P.

PA (GEHO) GEN HOSPITAL CORP.

PA (FARB) BAYER AG.

PI Woolf C, D'urso D, Befort K, Costigan M;

DR WPI; 2003-268312/26.

DR GENBANK; NP\_057672.

PT New composition comprising two or more isolated polypeptides, useful for

PT preparing a medicament for treating pain in an animal.

XX Claim 1; Page; 1017p; English.

CC The invention discloses a composition comprising two or more isolated rat  
CC or human polynucleotides or a polynucleotide which represents a fragment,

CC derivative or allelic variation of the nucleic acid sequence. Also  
CC claimed are a vector comprising the novel polynucleotide, a host cell  
CC comprising the vector, a method for identifying a nucleotide sequence  
CC which is differentially regulated in an animal subjected to pain and a  
CC kit to perform the method, an array, a method for identifying an agent  
CC that increases or decreases the expression of the polynucleotide sequence  
CC that is differentially expressed in neuronal tissue of a first animal  
CC subjected to pain, a method for identifying a compound which regulates  
CC the expression of a polynucleotide sequence which is differentially  
CC expressed in an animal subjected to pain, a method for identifying a  
CC compound that regulates the activity of one or more of the  
CC polynucleotides, a method for producing a pharmaceutical composition, a  
CC method for identifying a compound or small molecule that regulates the  
CC activity in an animal of one or more of the polypeptides given in the  
CC specification, a method for identifying a compound useful in treating  
CC pain and a pharmaceutical composition comprising the one or more  
CC polypeptides or their antibodies. The polynucleotide or the compound that  
CC modulates its activity is useful for preparing a medicament for treating  
CC pain (e.g. spinal segmental nerve injury (Chung), chronic constriction  
CC injury (CCI) and spared nerve injury (SNI)) in an animal (e.g. gene  
CC therapy). The sequence presented is a human protein (shown in Table 2 of  
CC the specification) which is differentially expressed during pain. Note:  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic form directly from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences.

SQ Sequence 142 AA:

Query Match 100.0%; Score 480; DB 7; Length 142;  
Best Local Similarity 100.0%; Pred. No. 1.3e-50;  
Matches 87; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGKCDVAFKGFSPDCLTKIGDSMANYPGGLDCKTNKTCYWEDEPHSCVTALTDCQEGA 60  
DB 28 AGKCDVAFKGFSPDCLTKIGDSMANYPGGLDCKTNKTCYWEDEPHSCVTALTDCQEGA 87  
QY 61 KDMWDKLRKESKNLNIQGSFLFELCGSG 87  
DB 88 KDMWDKLRKESKNLNIQGSFLFELCGSG 114

RESULT 10

ADN04842  
DB ADN04842 standard; protein; 142 AA.

AC ADN04842;

DT 01-JUL-2004 (first entry)

DE Antipsoriatic protein sequence #601.

XX antipsoriatic; gene therapy; psoriasis; diagnosis.

XX Homo sapiens.

PN W02004028479-A2.

XX 08-APR-2004.

PF 25-SEP-2003; 2003WO-US030907.

PR 25-SEP-2002; 2002US-0414006P.

XX (GETH) GENENTECH INC.

PI Godary S, Clark H, Jackman J, Schoenfeld J, Williams PM, Wood WI;

DR MPI; 2004-305105/28.

XX N-PSDB; ADN04841.

PT New PRO nucleic acid or polypeptide, useful for preparing a  
PS pharmaceutical composition for diagnosing or treating psoriasis in a

PT mammal.  
XX  
PS Claim 9; SEQ ID NO 1236; 3069BP; English.  
XX  
XX The invention relates to novel polynucleotide and polypeptides for  
CC treating psoriasis or a sequence having at least 80% identity to the  
CC above sequences. The nucleic acid is useful for preparing a composition  
CC for diagnosing or treating psoriasis in a mammal. This sequence  
CC corresponds to one of the polypeptides of the invention.

SQ Sequence 142 AA:

Query Match 100.0%; Score 480; DB 8; Length 142;  
Best Local Similarity 100.0%; Pred. No. 1.3e-50;  
Matches 87; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGKCDVAFKGFSPDCLTKIGDSMANYPGGLDCKTNKTCYWEDEPHSCVTALTDCQEGA 60  
DB 28 AGKCDVAFKGFSPDCLTKIGDSMANYPGGLDCKTNKTCYWEDEPHSCVTALTDCQEGA 87  
QY 61 KDMWDKLRKESKNLNIQGSFLFELCGSG 87  
DB 88 KDMWDKLRKESKNLNIQGSFLFELCGSG 114

RESULT 11

AAM41634  
ID AAM41634 standard; protein; 154 AA.

AC AAM41634;

DT 22-OCT-2001 (first entry)

DE Human polypeptide SEQ ID NO 6565.

XX Human; nocturnal; immunosuppressant; cytostatic; gene therapy; cancer;  
KW peripheral nervous system; neuropathy; central nervous system; CNS;  
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;  
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;  
KW chemokine; thrombolytic; drug screening; arthritis; inflammation;  
KW leukaemia.

XX Homo sapiens.

PN W0200153312-A1.

XX 26-JUL-2001.

PF 26-DEC-2000; 2000WO-US034263.

PR 23-DEC-1999; 99US-00471275.

PR 21-JAN-2000; 2000US-00488725.

PR 25-APR-2000; 2000US-00552317.

PR 20-JUN-2000; 2000US-00598042.

PR 19-JUL-2000; 2000US-00620312.

PR 03-AUG-2000; 2000US-00653450.

PR 14-SEP-2000; 2000US-00662191.

PR 19-OCT-2000; 2000US-00693036.

PR 29-NOV-2000; 2000US-00727344.

XX (HYSE-) HYSEQ INC.

XX Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;  
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J, Zhao QA;  
PI Zhou P, Goodrich R, Drmanac R;  
DR MPI; 2001-442253/47.  
XX N-PSDB; AAI60790.

PT Novel nucleic acids and polypeptides, useful for treating disorders such  
PS as central nervous system injuries.  
PS Example 2; SEQ ID NO 6565; 10078BP; English.







KW		neurodegenerative disorder; behavioural disorder; Alzheimer's disease;
KV		Parkinson's disease; Huntington's disease; schizophrenia; mania;
KX		dementia; paranoia; psychosis; autism; immune disorders; infection;
KY		Inflammation; allergy; liver disorder; hepatoblastoma; jaundice;
KZ		hepatitis; immunological disorder; AIDS; leukaemia; rheumatoid arthritis;
LX		Cancer.
XX		
OS		Unidentified.
PN		US6525174-B1.
PD		25-FEB-2003.
XX		
XX		
XX		
DE		04-DEC-1998; 98US-00205258.
PR		06-JUN-1997; 97US-0048897P.
PR		06-JUN-1997; 97US-0048876P.
PR		06-JUN-1997; 97US-0048877P.
PR		06-JUN-1997; 97US-0048878P.
PR		06-JUN-1997; 97US-0048880P.
PR		06-JUN-1997; 97US-0048881P.
PR		06-JUN-1997; 97US-0048882P.
PR		06-JUN-1997; 97US-0048883P.
PR		06-JUN-1997; 97US-0048884P.
PR		06-JUN-1997; 97US-0048885P.
PR		06-JUN-1997; 97US-0048892P.
PR		06-JUN-1997; 97US-0048893P.
PR		06-JUN-1997; 97US-0048894P.
PR		06-JUN-1997; 97US-0048895P.
PR		06-JUN-1997; 97US-0048896P.
PR		06-JUN-1997; 97US-0048897P.
PR		06-JUN-1997; 97US-0048898P.
PR		06-JUN-1997; 97US-0048899P.
PR		06-JUN-1997; 97US-0048900P.
PR		06-JUN-1997; 97US-0048901P.
PR		06-JUN-1997; 97US-0048902P.
PR		06-JUN-1997; 97US-0048903P.
PR		06-JUN-1997; 97US-0048904P.
PR		06-JUN-1997; 97US-0048905P.
PR		06-JUN-1997; 97US-0048906P.
PR		06-JUN-1997; 97US-0048907P.
PR		06-JUN-1997; 97US-0048908P.
PR		06-JUN-1997; 97US-0048909P.
PR		06-JUN-1997; 97US-0048910P.
PR		06-JUN-1997; 97US-0048911P.
PR		06-JUN-1997; 97US-0048912P.
PR		06-JUN-1997; 97US-0048913P.
PR		06-JUN-1997; 97US-0048914P.
PR		06-JUN-1997; 97US-0048915P.
PR		06-JUN-1997; 97US-0048916P.
PR		06-JUN-1997; 97US-0048917P.
PR		06-JUN-1997; 97US-0048918P.
PR		06-JUN-1997; 97US-0048919P.
PR		06-JUN-1997; 97US-0048920P.
PR		06-JUN-1997; 97US-0048921P.
PR		06-JUN-1997; 97US-0048922P.
PR		06-JUN-1997; 97US-0048923P.
PR		06-JUN-1997; 97US-0048924P.
PR		06-JUN-1997; 97US-0048925P.
PR		06-JUN-1997; 97US-0048926P.
PR		06-JUN-1997; 97US-0048927P.
PR		06-JUN-1997; 97US-0048928P.
PR		06-JUN-1997; 97US-0048929P.
PR		06-JUN-1997; 97US-0048930P.
PR		06-JUN-1997; 97US-0048931P.
PR		06-JUN-1997; 97US-0048932P.
PR		06-JUN-1997; 97US-0048933P.
PR		06-JUN-1997; 97US-0048934P.
PR		06-JUN-1997; 97US-0048935P.
PR		06-JUN-1997; 97US-0048936P.
PR		06-JUN-1997; 97US-0048937P.
PR		06-JUN-1997; 97US-0048938P.
PR		06-JUN-1997; 97US-0048939P.
PR		06-JUN-1997; 97US-0048940P.
PR		06-JUN-1997; 97US-0048941P.
PR		06-JUN-1997; 97US-0048942P.
PR		06-JUN-1997; 97US-0048943P.
PR		06-JUN-1997; 97US-0048944P.
PR		06-JUN-1997; 97US-0048945P.
PR		06-JUN-1997; 97US-0048946P.
PR		06-JUN-1997; 97US-0048947P.
PR		06-JUN-1997; 97US-0048948P.
PR		06-JUN-1997; 97US-0048949P.
PR		06-JUN-1997; 97US-0048950P.
PR		06-JUN-1997; 97US-0048951P.
PR		06-JUN-1997; 97US-0048952P.
PR		06-JUN-1997; 97US-0048953P.
PR		06-JUN-1997; 97US-0048954P.
PR		06-JUN-1997; 97US-0048955P.
PR		06-JUN-1997; 97US-0048956P.
PR		06-JUN-1997; 97US-0048957P.
PR		06-JUN-1997; 97US-0048958P.
PR		06-JUN-1997; 97US-0048959P.
PR		06-JUN-1997; 97US-0048960P.
PR		06-JUN-1997; 97US-0048961P.
PR		06-JUN-1997; 97US-0048962P.
PR		06-JUN-1997; 97US-0048963P.
PR		06-JUN-1997; 97US-0048964P.
PR		06-JUN-1997; 97US-0048965P.
PR		06-JUN-1997; 97US-0048966P.
PR		06-JUN-1997; 97US-0048967P.

```

PR 05-SEP-1997; 97US-0057760P.
PR 05-SEP-1997; 97US-0057761P.
PR 05-SEP-1997; 97US-0057762P.
PR 05-SEP-1997; 97US-0057763P.
PR 05-SEP-1997; 97US-0057764P.
PR 05-SEP-1997; 97US-0057765P.
PR 05-SEP-1997; 97US-0057769P.
PR 05-SEP-1997; 97US-0057770P.
PR 05-SEP-1997; 97US-0057771P.
PR 05-SEP-1997; 97US-0057774P.
PR 05-SEP-1997; 97US-0057775P.
PR 05-SEP-1997; 97US-0057776P.
PR 05-SEP-1997; 97US-0057777P.
PR 05-SEP-1997; 97US-0057778P.
PR 18-DEC-1997; 97US-0070323P.
PR 04-JUN-1998; 98WO-US01142Z.
PR 15-JUL-1998; 98US-0092921P.
PR 30-JUL-1998; 98US-0094657P.
XX
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
XX Young P, Greene JM, Perrie AM, Ruben SM, Rosen CA, Hu J,
PI Olsen HS, Ebner R, Brewer LA, Moore PA, Shi Y, Florence C,
PI Florence K, Lefleur DW, Ni J, Fan P, Wei Y, Fischer CL, Soppet DR,
PI Li Y, Zeng Z, Kyaw H, Yu G, Peng P, Dillon PJ, Endress GA,
PI Carter KC;
XX
XX WPI; 2003-511926/48.
XX
XX New precerebellin-like protein, useful for diagnosing or treating
XX neurodegenerative and behavioral disorders, immune disorders, liver
XX disorders, and cancer.
XX
XX Disclosure; Col 213; 156P; English.
XX
XX The invention relates to an isolated protein comprising amino acid
XX residues 33-205 or 1-205 of a novel human secreted protein appearing as
XX ABO2652. The protein is encoded by one of 238 disclosed cDNA sequences
XX encoding 238 secreted proteins. ABO26252 is a precerebellin-like protein.
XX Also included are a composition comprising the protein and a carrier and
XX an isolated protein produced by expressing the protein cited above by a
XX cell, and recovering the protein. The proteins are useful for diagnosing
XX or treating neurodegenerative and behavioral disorders (e.g. Alzheimer's
XX disease, Parkinson's disease, Huntington's disease, schizophrenia, mania,
XX dementia, Parainfluenza, psychoses or autism), immune disorders (e.g.
XX infection, inflammation, allergy), liver disorders (e.g. hepatoblastoma,
XX jaundice, hepatitis), immunological disorders (e.g. AIDS, leukaemia,
XX rheumatoid arthritis, sepsis, acne, psoriasis) and cancer. The present
XX sequence is a protein associated with one of the 238 disclosed novel
XX secreted proteins
XX
XX
XX Sequence 143 AA:
XX
XX Query Match. 88.9%; Score 426.5; DB 7; Length 143;
XX Best Local Similarity 90.9%; Pred. No. 5e-44; 7; Indels 1; Gaps 1.1
XX Matches 80; Conservative 0; Mismatches 7;
XX
XX 1 AGKCAVFKGFSDDLKLGDS-MANVQGLDDKNTIKTVCTWEDPHSCTVATLDCQG 59
XX 28 AGKCAVFKGFSDDLKLGDSXXXXXXPAWDDKNTIKTVCTWEDPHSCTVATLDCQG 87
XX
XX 60 AKDWDKLRKESKNLNIQSLFELCGSG 87
XX
XX 88 AKDWDKLRKESKNLNIQSLFELCGSG 115
XX

```

Tue Dec 21 15:50:46 2004

us-10-670-911a-1.rapb

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: December 20, 2004, 15:18:36 ; Search time 144 Seconds  
(without alignments)  
216.192 Million cell updates/sec

Title: US-10-670-911A-1

Perfect score: 480  
Sequence: 1 AGKCDVAFKGFSDCLKLDG.....RKESKNLNTQGSIFELCGSG 87

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1589859 seqs, 357834939 residues

Total number of hits satisfying chosen parameters: 1589859

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA:  
1: /cgn2\_6/ptodata/1/pubpaa/US07\_PUBCOMB.pep:\*  
2: /cgn2\_6/ptodata/1/pubpaa/US06\_NEW\_PUB.pep:\*  
3: /cgn2\_6/ptodata/1/pubpaa/US06\_NEW\_PUB.pep:\*  
4: /cgn2\_6/ptodata/1/pubpaa/US06\_PUBCOMB.pep:\*  
5: /cgn2\_6/ptodata/1/pubpaa/US07\_NEW\_PUB.pep:\*  
6: /cgn2\_6/ptodata/1/pubpaa/US07\_PUBCOMB.pep:\*  
7: /cgn2\_6/ptodata/1/pubpaa/US08\_NEW\_PUB.pep:\*  
8: /cgn2\_6/ptodata/1/pubpaa/US08\_PUBCOMB.pep:\*  
9: /cgn2\_6/ptodata/1/pubpaa/US09\_PUBCOMB.pep:\*  
10: /cgn2\_6/ptodata/1/pubpaa/US09\_PUBCOMB.pep:\*  
11: /cgn2\_6/ptodata/1/pubpaa/US09C\_PUBCOMB.pep:\*  
12: /cgn2\_6/ptodata/1/pubpaa/US09C\_PUBCOMB.pep:\*  
13: /cgn2\_6/ptodata/1/pubpaa/US10\_PUBCOMB.pep:\*  
14: /cgn2\_6/ptodata/1/pubpaa/US10\_PUBCOMB.pep:\*  
15: /cgn2\_6/ptodata/1/pubpaa/US10C\_PUBCOMB.pep:\*  
16: /cgn2\_6/ptodata/1/pubpaa/US10D\_PUBCOMB.pep:\*  
17: /cgn2\_6/ptodata/1/pubpaa/US10\_NEW\_PUB.pep:\*  
18: /cgn2\_6/ptodata/1/pubpaa/US10\_NEW\_PUB.pep:\*  
19: /cgn2\_6/ptodata/1/pubpaa/US60\_NEW\_PUB.pep:\*  
20: /cgn2\_6/ptodata/1/pubpaa/US60\_PUBCOMB.pep:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	480	100.0	87	16 US-10-670-911A-1	Sequence 1, Appli
2	426.5	88.9	143	10 US-09-933-767-1202	Sequence 1202, Ap
3	426.5	88.9	143	14 US-10-004-860-1202	Sequence 1202, Ap
4	426.5	88.9	143	14 US-10-023-282-1202	Sequence 1202, Ap
5	327	68.1	90	10 US-09-933-767-1201	Sequence 1201, Ap
6	327	68.1	90	14 US-10-004-860-1201	Sequence 1201, Ap
7	327	68.1	90	14 US-10-023-282-1201	Sequence 1201, Ap
8	179.5	37.4	165	13 US-10-001-054-44	Sequence 44, Appl
9	179.5	37.4	165	14 US-10-227-884-230	Sequence 230, App
10	179.5	37.4	165	14 US-10-230-163-230	Sequence 230, App
11	179.5	37.4	165	14 US-10-230-338-230	Sequence 230, App
12	179.5	37.4	165	14 US-10-218-631-230	Sequence 230, App
13	179.5	37.4	165	14 US-10-230-414-230	Sequence 230, App

14	179.5	37.4	165	14	US-10-232-224-230	Sequence 230, App
15	179.5	37.4	165	14	US-10-216-159A-230	Sequence 230, App
16	179.5	37.4	165	14	US-10-218-449-230	Sequence 230, App
17	179.5	37.4	165	14	US-10-227-873-230	Sequence 230, App
18	179.5	37.4	165	14	US-10-227-883-230	Sequence 230, App
19	179.5	37.4	165	14	US-10-219-076-230	Sequence 230, App
20	179.5	37.4	165	14	US-10-230-434-230	Sequence 230, App
21	179.5	37.4	165	14	US-10-219-003-230	Sequence 230, App
22	179.5	37.4	165	14	US-10-219-464-230	Sequence 230, App
23	179.5	37.4	165	14	US-10-219-466-230	Sequence 230, App
24	179.5	37.4	165	14	US-10-219-479-230	Sequence 230, App
25	179.5	37.4	165	14	US-10-219-481-230	Sequence 230, App
26	179.5	37.4	165	14	US-10-230-260-230	Sequence 230, App
27	179.5	37.4	165	14	US-10-232-331-230	Sequence 230, App
28	179.5	37.4	165	14	US-10-232-333-230	Sequence 230, App
29	179.5	37.4	165	14	US-10-219-536-230	Sequence 230, App
30	179.5	37.4	165	14	US-10-216-165-230	Sequence 230, App
31	179.5	37.4	165	14	US-10-218-956-230	Sequence 230, App
32	179.5	37.4	165	14	US-10-219-468-230	Sequence 230, App
33	179.5	37.4	165	14	US-10-219-478-230	Sequence 230, App
34	179.5	37.4	165	14	US-10-219-528-230	Sequence 230, App
35	179.5	37.4	165	14	US-10-227-880-230	Sequence 230, App
36	179.5	37.4	165	14	US-10-227-881-230	Sequence 230, App
37	179.5	37.4	165	14	US-10-227-882-230	Sequence 230, App
38	179.5	37.4	165	14	US-10-227-883-230	Sequence 230, App
39	179.5	37.4	165	14	US-10-219-524-230	Sequence 230, App
40	179.5	37.4	165	14	US-10-219-528-230	Sequence 230, App
41	179.5	37.4	165	14	US-10-227-880-230	Sequence 230, App
42	179.5	37.4	165	14	US-10-227-881-230	Sequence 230, App
43	179.5	37.4	165	14	US-10-227-882-230	Sequence 230, App
44	179.5	37.4	165	14	US-10-232-223-230	Sequence 230, App
45	179.5	37.4	165	14	US-10-232-223-230	Sequence 230, App

#### ALIGNMENTS

RESULT 1  
US-10-670-911A-1  
; Sequence 1, Application US/10670911A  
; Publication No. US20040176291A1  
; GENERAL INFORMATION:  
; APPLICANT: Mediva, Eli Lilly  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR SOLUBLE CPG  
; FILE REFERENCE: 01997/547002  
; CURRENT FILING DATE: 2003-09-24  
; PRIOR APPLICATION NUMBER: US 60/413, 238  
; PRIOR FILING DATE: 2002-09-24  
; NUMBER OF SEQ ID NOS: 3  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 1  
; LENGTH: 87  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-670-911A-1

Query Match 100.0%; Score 480; DB 16; Length 87;  
Best Local Similarity 100.0%; Pred. No. 1.1e-48;  
Matches 87; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGKCDVAFKGFSDCLKLDGSMANYPOGLDKNIKTVCTYWEDEFSCTVATLDDCEGA 60  
DB 1 AGKCDVAFKGFSDCLKLDGSMANYPOGLDKNIKTVCTYWEDEFSCTVATLDDCEGA 60  
QY 61 KDWMDKLRKESKNLNTQGSIFELCGSG 87  
DB 61 KDWMDKLRKESKNLNTQGSIFELCGSG 87

RESULT 2  
US-09-933-767-1202

Sequence 1202, Application US/09333767  
Publication No. US20030181692A1  
GENERAL INFORMATION:  
APPLICANT: Ni et al.  
TITLE OF INVENTION: 207 Human Secreted Proteins  
FILE REFERENCE: P2007P2  
CURRENT APPLICATION NUMBER: US/09/933,767  
CURRENT FILING DATE: 2001-08-22  
PRIOR APPLICATION NUMBER: PCT/US01/05614  
PRIOR FILING DATE: 2001-02-21  
PRIOR APPLICATION NUMBER: 60/184,835  
PRIOR FILING DATE: 2000-02-24  
PRIOR APPLICATION NUMBER: 60/193,170  
PRIOR FILING DATE: 2000-03-29  
PRIOR APPLICATION NUMBER: 09/205,258  
PRIOR FILING DATE: 1998-12-04  
PRIOR APPLICATION NUMBER: PCT/US96/11422  
PRIOR FILING DATE: 1998-06-04  
PRIOR APPLICATION NUMBER: 60/048,885  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/049,375  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/048,881  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/048,880  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/048,896  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/049,020  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/048,876  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/048,895  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/048,884  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/048,894  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/048,971  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/048,964  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/048,882  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/048,899  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/048,893  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/048,900  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/048,901  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/048,892  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/048,915  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/049,019  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/048,970  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/048,972  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/048,916  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/049,373  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/048,875  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/049,374  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/048,917  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/048,949

PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/048,974  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/048,883  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/048,897  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/048,898  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/048,962  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/048,963  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/048,877  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/048,878  
PRIOR FILING DATE: 1997-06-06  
PRIOR APPLICATION NUMBER: 60/068,054  
PRIOR FILING DATE: 1997-12-18  
PRIOR APPLICATION NUMBER: 60/068,064  
PRIOR FILING DATE: 1997-12-18  
PRIOR APPLICATION NUMBER: 60/068,053  
PRIOR FILING DATE: 1997-12-18  
PRIOR APPLICATION NUMBER: 60/070,923  
PRIOR FILING DATE: 1997-12-18  
PRIOR APPLICATION NUMBER: 60/073,160  
PRIOR FILING DATE: 1998-01-30  
PRIOR APPLICATION NUMBER: 60/073,159  
PRIOR FILING DATE: 1998-01-30  
PRIOR APPLICATION NUMBER: 60/073,165  
PRIOR FILING DATE: 1998-01-30  
PRIOR APPLICATION NUMBER: 60/073,164  
PRIOR FILING DATE: 1998-01-30  
PRIOR APPLICATION NUMBER: 60/085,925  
PRIOR FILING DATE: 1998-05-18  
PRIOR APPLICATION NUMBER: 60/085,921  
PRIOR FILING DATE: 1998-05-18  
PRIOR APPLICATION NUMBER: 60/085,923  
PRIOR FILING DATE: 1998-05-18  
PRIOR APPLICATION NUMBER: 60/085,922  
PRIOR FILING DATE: 1998-05-18  
PRIOR APPLICATION NUMBER: 60/092,921  
PRIOR FILING DATE: 1998-07-15  
PRIOR APPLICATION NUMBER: 60/094,557  
PRIOR FILING DATE: 1998-07-30  
NUMBER OF SEQ ID NOS: 1245  
SOFTWARE: PatentIn Ver. 2.0  
SEQ ID NO 1202  
LENGTH: 143  
TYPE: PRT  
ORGANISM: Homo sapiens  
FEATURES:  
NAME/KEY: SITE  
LOCATION: (49)  
OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
NAME/KEY: SITE  
LOCATION: (50)  
OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
NAME/KEY: SITE  
LOCATION: (51)  
OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
NAME/KEY: SITE  
LOCATION: (52)  
OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
NAME/KEY: SITE  
LOCATION: (53)  
OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
US-09-933-767-1202  
Query Match 88.9%; Score 426.5; DB 10; Length 143;  
Best Local Similarity 90.9%; Pred. No. 48-42;  
Matches 80; Conservative 0; Mismatches 7; Indels 1; Gaps 1;

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: December 20, 2004, 15:13:37 ; Search time 16 Seconds  
(without alignments)  
523.179 Million cell updates/sec

Title: US-10-670-911a-1

Perfect score: 480

Sequence: 1 AKKCDVAFKGFSDCLKLGD.....RKESKNINQGSLEFELCGSG 87

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database:

1: PIR1:\*  
2: PIR2:\*  
3: PIR3:\*  
4: PIR4:\*

# SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	480	100.0	142	2	JC6305
2	76.5	15.9	2241	2	T20971
3	76.5	15.9	2261	2	T20971
4	71.5	14.9	195	2	H88996
5	71.5	14.9	2269	2	T28677
6	71	14.8	199	2	T28981
7	71	14.8	340	2	B84019
8	70	14.6	609	2	E81500
9	70	14.6	609	2	H72038
10	70	14.6	609	2	H86584
11	69	14.4	290	2	AH1681
12	69	14.4	305	2	JC5844
13	68	14.2	444	1	M1WLS8
14	67	14.0	442	2	T01731
15	66	13.8	429	2	E84952
16	66	13.6	201	2	F85071
17	65.5	13.6	201	2	F88990
18	65	13.5	184	2	C88104
19	65	13.5	322	2	T20423
20	65	13.5	433	2	T25946
21	65	13.5	483	2	T19720
22	64.5	13.4	231	2	D66925
23	64.5	13.4	751	2	H90410
24	64	13.3	256	2	G96692
25	64	13.3	1016	2	T49686
26	63.5	13.2	788	2	T25061
27	63	13.1	1792	2	T08878
28	63	13.1	2718	2	A23475
29	62.5	13.0	211	2	T01194

30	62.5	13.0	1127	2	T30334
31	62.5	13.0	1863	2	G82875
32	62.5	13.0	2098	2	T18397
33	62	12.9	1179	2	T04584
34	62	12.9	1365	2	T30198
35	61.5	12.8	99	2	S21461
36	61.5	12.8	331	2	F86633
37	61.5	12.8	372	1	VVVPK1
38	61.5	12.8	612	2	H66323
39	61.5	12.8	701	2	S48452
40	61.5	12.8	1276	2	S75801
41	61	12.7	430	2	D64151
42	61	12.7	467	2	A81590
43	61	12.7	533	1	S75536
44	61	12.7	1132	2	H82887
45	60.5	12.6	250	2	T29866

## ALIGNMENTS

### RESULT 1

JC6305

C/Species: Rattus norvegicus (Norway rat)

C/Date: 21-May-1998 #sequence\_revision 29-May-1998 #text\_change 09-Jul-2004

C/Accession: JC6305

R/Naevae, G.S.; Ramakrishnan, M.; Kramer, R.; Heyroni, D.; Cleri, Y.; Theill, L.E.

Proc. Natl. Acad. Sci. U.S.A. 94, 2648-2653, 1997

A/Title: Neuritin: A gene induced by neural activity and neurotrophins that promotes ne

A/Reference number: JC6305; MUID:97226008; PMID:9122250

A/Accession: JC6305

A/Molecule type: mRNA

A/Residues: 1-142 <NAE>

A/Cross-references: UNIPROT:008957; GB:U88950

C/Comment: This protein promotes neurite outgrowth and arborization in primary embryoni

C/Supfamily: rat neuritin

C/Keywords: blocked carboxyl end; disulfide bond; glycoprotein; lipoprotein; phosphatid

F:1-27/Domain: signal sequence #status predicted <SIG>

F:28-115/Product: neuritin #status predicted <MTR>

F:116-142/Domain: carboxyl-terminal propeptide #status predicted <CTP>

F:115/Modified site: GPI-anchor ethanolamine amidated carboxyl end (Asn) (in mature for

Query Match

Best Local Similarity 100.0%; Score 480; DB 2; Length 142;

Matches 87; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AKKCDVAFKGFSDCLKLGDSDMANYPOGLDKNIKVCTYWEFPHSCVTALTDCEGA 60

DB 28 AKKCDVAFKGFSDCLKLGDSDMANYPOGLDKNIKVCTYWEFPHSCVTALTDCEGA 87

QY 61 KQMDKLRKESKNINQGSLEFELCGSG 87

DB 88 KQMDKLRKESKNINQGSLEFELCGSG 114

### RESULT 2

T20971

C/Species: Caenorhabditis elegans

C/Date: 15-Oct-1999 #sequence\_revision 15-Oct-1999 #text\_change 15-Oct-1999

C/Accession: T20971

R/White, S.

submitted to the EMBL Data Library, October 1996

A/Reference number: Z19353

A/Accession: T20971

A/Status: preliminary; translated from GB/EMBL/DBJ

A/Molecule type: DNA

A/Residues: 1-2241 <WIL>

A/Cross-references: EMBL:Z81063; PIDD:CA802951.1; GSPDB:GN00019; CESP:FL15D3.1

A/Experimental source: clone F15D3

C/Genetics:

A/Genes: CESP:FL15D3.1

A:Map position: 1  
A:Insertions: 24/1; 130/3; 172/2; 194/2; 206/1; 235/3; 297/3; 438/2; 497/3; 601/2; 737/3; 866/3; 2019/3; 2044/3

Query Match 15.9%; Score 76.5; DB 2; Length 2241;  
Best Local Similarity 31.0%; Pred. No. 7.3;  
Matches 22; Conservative 10; Mismatches 26; Indels 13; Gaps 2;

QY 9 KGFSDCLIKLGDGMANYPOGLDPTKNIKTCTYWEDEPHSC-----TWTALTDQEGAKDM 63  
DB 1309 KGFEEKLEKVTITLSNVEMGLDPTGT-----DGSECGALMEVRLVRLMDQAGK 1360

QY 64 WDKLRKESKYL 74  
DB 1361 WKDLAENREQ 1371

## RESULT 3

T20978  
Hypothetical protein F15D3.9 - Caenorhabditis elegans

C:Species: Caenorhabditis elegans

C:Date: 15-Oct-1999 #sequence\_revision 15-Oct-1999 #text\_change 15-Oct-1999

C:Accession: T20978

R:Name: S.

Submitted to the EMBL Data Library, October 1996

A:Reference number: Z19353

A:Accession: T20978

A:Status: preliminary; translated from GB/EMBL/DBJ

A:Molecule type: DNA

A:Residues: 1-2261 <ML>

A:Cross-references: EMBL:Z81063; PIDN:CA802958.1; GSPDB:GN00019; CESP:F15D3.9

A:Experimental source: clone F15D3

C:Genetics:

A:Gene: CESP:F15D3.9

A:Map position: 1

A:Insertions: 24/1; 130/3; 172/2; 211/1; 240/3; 302/3; 443/2; 502/3; 606/2; 742/3; 828/2; 906/3

Query Match 15.9%; Score 76.5; DB 2; Length 2261;  
Best Local Similarity 31.0%; Pred. No. 7.3; 26; Indels 13; Gaps 2;

Matches 22; Conservative 10; Mismatches 26; Indels 13; Gaps 2;

QY 9 KGFSDCLIKLGDGMANYPOGLDPTKNIKTCTYWEDEPHSC-----TWTALTDQEGAKDM 63

DB 1289 KGFEEKLEKVTITLSNVEMGLDPTGT-----DGSECGALMEVRLVRLMDQAGK 1340

QY 64 WDKLRKESKYL 74

DB 1341 WKDLAENREQ 1351

## RESULT 4

H88996  
Protein C17B7.4 (imported) - Caenorhabditis elegans

C:Species: Caenorhabditis elegans

C:Date: 10-May-2001 #sequence\_revision 10-May-2001 #text\_change 09-Jul-2004

C:Accession: H88996

R:Anonymous, The C. elegans Sequencing Consortium.

Science 287, 2012-2018, 1998

A:Title: Genome sequence of the nematode C. elegans: a platform for investigating biology

A:Reference number: A75600; MIMD:95069613; PMID:9551916

A:Note: see websites genome.wustl.edu/gsc/C\_elegans/ and www.sanger.ac.uk/Projects/C\_ele

A:Note: published errata appeared in Science 283, 35, 1999; Science 283, 2103, 1999; and

A:Accession: H88996

A:Status: preliminary

A:Molecule type: DNA

A:Residues: 1-195 <STO>

A:Cross-references: UNIPROT:O45156; GB:chr\_V; PIDN:AAC04398.1; PID:G2911826; GSPDB:GN000

C:Genetics:

A:Gene: C17B7.4

A:Map position: 5

C:Superfamily: Caenorhabditis elegans hypothetical protein C01B7.7

Query Match 14.9%; Score 71.5; DB 2; Length 195;  
Best Local Similarity 31.0%; Pred. No. 1.8;  
Matches 27; Conservative 10; Mismatches 37; Indels 13; Gaps 5;

QY 5 DAVKGFSDCLIKLGDGMANYPOGLDPTKNIKTCTYWEDEPHSCVTAALTDQEG 59  
DB 37 ELTRKGFVCLYRGDFMTXN-YFLDVKSPNSNKRFTSLSMAD---CTES--FECONN 90

QY 60 AK--DMWDKLRKESKNIQSLPELC 84  
DB 91 KEPTDSKRVRESCELTNFGTDPTTC 117

## RESULT 5

T28677  
rhodopy protein - Plasmodium yoelii

C:Species: Plasmodium yoelii

C:Date: 15-Oct-1999 #sequence\_revision 15-Oct-1999 #text\_change 09-Jul-2004

C:Accession: T28677; C45521

R:Keen, J.; Sinha, K.; Brown, K.; Holder, A.

Mol. Biochem. Parasitol. 65, 171-177, 1994

A:Title: A gene coding for a high molecular mass rhodopy protein of Plasmodium yoelii

A:Reference number: Z20508; MIMD:95021522; PMID:7935623

A:Accession: T28677

A:Status: preliminary; translated from GB/EMBL/DBJ

A:Molecule type: DNA

A:Residues: 1-2269 <KRB>

A:Cross-references: UNIPROT:Q26223; EMBL:L27838; NID:9457145; PID:9457146; PIDN:AA0210

R:Keen, J.; Holder, A.; Playfair, J.; Lockyer, M.; Lewis, A.

Mol. Biochem. Parasitol. 42, 241-246, 1990

A:Title: Identification of the gene for a Plasmodium yoelii rhodopy protein. Multiple

A:Reference number: A45521; MIMD:91101660; PMID:2270106

A:Accession: C45521

A:Status: preliminary

A:Molecule type: DNA

A:Residues: 2131-2269 <KRB>

A:Cross-references: GB:M34283

Query Match 14.9%; Score 71.5; DB 2; Length 2269;  
Best Local Similarity 22.8%; Pred. No. 26;  
Matches 23; Conservative 21; Mismatches 32; Indels 25; Gaps 3;

QY 8 KGFSDCLIKLGDGMANYPOGLDPTKNIKTCTYWEDEPHSCV 50

DB 15 FKLGNEMIKLXNSGLRKTTISQIKKLNVTYEGRGFTSSLELAKSWKTKLETI 74

QY 51 TALTDQEG-----KDMWDKLRKESKNIQSLPELC 83

DB 75 TELTKSNETVRLKEIRELFKRYLDEAEKRYLLEKLEL 115

## RESULT 6

T28981  
hypothetical protein T28A11.16 - Caenorhabditis elegans

C:Species: Caenorhabditis elegans

C:Date: 29-Oct-1999 #sequence\_revision 29-Oct-1999 #text\_change 09-Jul-2004

C:Accession: T28981

R:Roehlfing, T.

Submitted to the EMBL Data Library, January 1997

A:Description: The sequence of C. elegans cosmid T28A11.

A:Reference number: Z20550

A:Accession: T28981

A:Status: preliminary; translated from GB/EMBL/DBJ

A:Molecule type: DNA

A:Residues: 1-199 <ROH>

A:Cross-references: UNIPROT:P91512; EMBL:U80027; PIDN:AAC48125.1; GSPDB:GN00023; GSPDB

A:Experimental source: strain Bristol N2; clone T28A11

C:Genetics:

A:Gene: CESP:T28A11.16

A:Map position: 5

A:Insertions: 53/3; 183/3

C:Superfamily: Caenorhabditis elegans hypothetical protein C01B7.7